Lime & Lemon Apex Redefines the Dining Scene with an Experience the Triangle Was Waiting For GlobeNewswire December 07, 2025 Apex, NC, Dec. 07, 2025 (GLOBE NEWSWIRE) — When Lime & Lemon opened its doors in Apex, it was more than just the arrival of another restaurant. It marked the introduction of a new kind […]
New York, New York–(Newsfile Corp. – December 7, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers or sellers of common stock of Cepton, Inc. (NASDAQ: CPTN) between July 29, 2024 and January 6, 2025, both dates inclusive (the “Class Period”), of the important December 8, 2025 lead plaintiff deadline.
FOR IMMEDIATE RELEASE — ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025 — Updated clinical data presented at ASH show robust efficacy, rapid onset of remission, high incidence of MRD1-negativity, and an encouraging survival signal with ICT01 in combination with azacitidine and venetoclax (Aza-Ven) in newly
ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025 GlobeNewswire December 07, 2025 FOR IMMEDIATE RELEASE — ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025 — Updated clinical data presented at ASH show robust efficacy, rapid onset of
DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease features A 12-day manufacturing time resulted in a vein-to-vein time
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting GlobeNewswire December 07, 2025 DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was
New York, New York–(Newsfile Corp. – December 7, 2025) – Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Blue Owl Capital Inc. (NYSE: OWL) between February 6, 2025 and November 16, 2025. A class action lawsuit has already been filed. If you
New York, New York–(Newsfile Corp. – December 7, 2025) – Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Alexandria Real Estate Equities, Inc. (NYSE: ARE) between January 27, 2025 and October 27, 2025, both dates inclusive (the “Class Period”). A class action
New York, New York–(Newsfile Corp. – December 7, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Perrigo Company plc (NYSE: PRGO) between February 27, 2023 and November 4, 2025, both dates inclusive (the “Class Period”), of the important January 16, 2026 lead plaintiff deadline. SO WHAT:
New York, New York–(Newsfile Corp. – December 7, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Inspire Medical Systems, Inc. (NYSE: INSP) between August 6, 2024 and August 4, 2025, both dates inclusive (the “Class Period”), of the important January 5, 2026 lead plaintiff deadline. SO